HER2 (also known as ERBB2) is a key oncogene in breast cancer and is found in 2–4% of patients with non-small-cell lung ...

Sanofi's Sarclisa (isatuximab) has gained approval from Japan’s Ministry of Health, Labour and Welfare for use in conjunction ...

Each episode of this journey through a disease state contains both a physician guide and a downloadable/printable patient ...

Narrow-moat-rated Repligen is a leading provider of bioprocessing solutions for companies that manufacture biologic drugs. Its business lines include advanced filtration and fluid management systems ...

GSK (GSK) announced that the China National Medical Products Administration, CNMPA, has accepted for review the new drug application for the ...

Understanding biosimilars, biologics, and the challenges surrounding their regulation and pricing in the pharmaceutical ...

The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for reviewing a New Drug Application (NDA) or Biologics License Application (BLA ...

Mason Conner, a five-year-old previously nonverbal autistic boy from Arizona, finally said his first words just days after he ...

Peptide therapy enhances targeted medicine, utilizing specific peptides for effective treatment of cancer, metabolic disorders, and neurodegenerative diseases.

OBODENCE, referencing Prolia, has been approved for the treatment of osteoporosis in postmenopausal ... with reference denosumab in healthy male subjects. Expert Opin Investig Drugs. 2023 ...

This didn’t stop other monoclonal antibodies from being pursued in the clinic. Still, setbacks continued as these drugs did not succeed in slowing cognitive decline in patients even if they were ...

While only a few antibodies were approved in the immediate years that followed the rituximab approval, the last decade saw a wave of antibody-drug approvals in the oncology arena. In the last three ...